TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Why we love this deal Finding alternate modes of transportation is Read more…
The political promise has been on the books since last July. Now the IRS has turned it into an actual list of jobs. The Department of the Treasury and the Internal Revenue Service issued final Read more…
An influential former Federal Reserve official says the legal protections barring members of the Fed Board of Governors from removal by the president except for cause should be overturned. Former Federal Reserve Vice Chair for Read more…
Dividend stocks can be quiet wealth-builders. The income doesn’t arrive with fanfare but shows up quarter after quarter, while compounding over time. That’s a powerful reality that Warren Buffett learned a long time ago. Dividend Read more…
Retail store closures have become increasingly common worldwide amid macroeconomic pressure and shifting consumer behavior. However, some exits are driven by factors beyond financial performance, highlighting the growing role of geopolitical risk in shaping global Read more…
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Why we love this deal Extra storage is never a bad Read more…
ECB President Christine Lagarde pushed back against rising market expectations for near-term rate hikes, signaling caution despite the energy shock from the Middle East conflict. Investors have increasingly priced the risk of tightening as the Read more…
The IMF has warned that the global economy faces a more prolonged and damaging shock if the Middle East conflict escalates, with oil prices potentially averaging as high as $125 in 2027 under a severe Read more…
As the economy struggles, and many Americans look for ways to save money, Costco has proven resilient. The chain has continued to grow its membership and retain nearly 90% of its members worldwide, “At Q2 Read more…
Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for a second time, sending shares down approximately 64% and forcing management into cost-cutting mode. The market is Read more…